NCT01774370View on ClinicalTrials.gov

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

CompletedOBSERVATIONAL
Enrollment

3,182

Participants

Timeline

Start Date

January 14, 2013

Primary Completion Date

February 17, 2017

Study Completion Date

February 17, 2017

Conditions
Atrial Fibrillation
Interventions
DRUG

Pradaxa (Dabigatran etexilate mesilate)

110 mg or 150 mg b.i.d.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY